文献速递妇科

针对卵巢癌女性PARP抑制剂相关疲乏的接纳基础远程医疗干预试点随机试验

Pilot randomized trial of an acceptance-based telehealth intervention for women with ovarian cancer and PARP inhibitor-related fatigue.
PubMed 文献 · Gynecol Oncol · 2023-09-13

在接受PARP抑制剂(PARPi)的晚期卵巢癌患者中,约半数出现显著疲乏;本研究为两中心试点随机试验,将44例患者按1:1随机分配至REVITALIZE组或强化常规照护组,评估简短接纳基础远程医疗干预的可行性、可接受性和初步疗效,结果显示干预可行可接受,并在改善疲乏干扰、严重程度和水平方面显示初步疗效。

要点

  • REVITALIZE组12周时疲乏干扰较强化常规照护组显著降低(Cohen's d=0.94,p=.008)。
  • REVITALIZE组疲乏严重程度(d=0.54,p=.049)和疲乏水平(d=0.62,p=.04)较强化常规照护组显著改善。
  • REVITALIZE组PARPi剂量减少(6.7% vs 19.0%)和剂量延迟(6.7% vs 23.8%)例数少于强化常规照护组。

核心结论

  • 在接受PARPi的疲乏卵巢癌成人患者中,简短接纳基础远程医疗干预可行、可接受,并在改善疲乏干扰、严重程度和水平方面显示初步疗效。
  • REVITALIZE是一种新颖、可扩展的远程医疗干预,值得进一步研究。

研究设计与样本

  • 两中心试点随机试验,2021年6月至2022年4月,44例参与者按1:1随机分配至REVITALIZE组(6次每周一对一课程+强化课程)或强化常规照护组。
  • 可行性定义为:潜在合格患者中≥50%同意参与,且≥70%完成12周随访评估;可接受性定义为:<20%参与者报告负担且<20%研究退出。
  • 在基线、4周、8周和12周评估疲乏、焦虑、抑郁和生活质量。

主要发现

  • 44例参与者平均年龄62.5岁,81.8%为III/IV期疾病;研究可行(同意参与比例56.4%,12周评估完成率86.3%)且可接受(0%报告负担,11.3%研究退出)。
  • 12周随访时,REVITALIZE组较强化常规照护组显著降低疲乏干扰(Cohen's d=0.94,p=.008)和疲乏严重程度(d=0.54,p=.049),并改善疲乏水平(d=0.62,p=.04)。
  • REVITALIZE组在改善疲乏自我效能、疲乏灾难化、焦虑、抑郁和生活质量方面显示希望(ds=0.60-0.86,p≥.05)。
  • REVITALIZE组较强化常规照护组PARPi剂量减少更少(6.7% vs 19.0%),剂量延迟更少(6.7% vs 23.8%)。

关键数值与推荐

  • 可行性标准:潜在合格患者中≥50%同意参与,且≥70%完成12周随访评估;可接受性标准:<20%参与者报告负担且<20%研究退出。
  • REVITALIZE组12周时疲乏干扰效应量Cohen's d=0.94(p=.008),疲乏严重程度d=0.54(p=.049),疲乏水平d=0.62(p=.04)。
  • REVITALIZE组PARPi剂量减少6.7%,强化常规照护组19.0%;REVITALIZE组剂量延迟6.7%,强化常规照护组23.8%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Poly(ADP-ribose) polymerase inhibitors (PARPi) have dramatically changed treatment for advanced ovarian cancer, but nearly half of patients experience significant fatigue. We conducted a two-site pilot randomized trial to evaluate the feasibility, acceptability, and preliminary efficacy of a brief, acceptance-based telehealth intervention (REVITALIZE) designed to reduce fatigue interference in patients on PARPi. METHODS: From June 2021 to April 2022, 44 participants were randomized 1:1 to REVITALIZE (6 weekly one-on-one sessions+booster) or enhanced usual care. Feasibility was defined as: ≥50% approach-to-consent among potentially eligible patients and ≥70% completion of 12-week follow-up assessment; acceptance was <20% participants reporting burden and <20% study withdrawal. Fatigue, anxiety, depression, and quality of life were assessed at baseline, 4-, 8- and 12-weeks. RESULTS: Among 44 participants (mean age = 62.5 years, 81.8% stage III/IV disease), the study was feasible (56.4% approach-to-consent ratio, 86.3% completion of 12-week assessment) and acceptable (0% reporting burden, 11.3% study withdrawal). At 12-week follow-up, REVITALIZE significantly reduced fatigue interference (Cohen's d = 0.94, p = .008) and fatigue severity (d = 0.54, p = .049), and improved fatigue levels (d = 0.62, p = .04) relative to enhanced usual care. REVITALIZE also showed promise for improved fatigue self-efficacy, fatigue catastrophizing, anxiety, depression, and quality of life (ds = 0.60-0.86, p ≥ .05). Compared with enhanced usual care, REVITALIZE participants had fewer PARPi dose reductions (6.7% vs. 19.0%), and dose delays (6.7% vs. 23.8%). CONCLUSIONS: Among fatigued adults with ovarian cancer on PARPi, a brief, acceptance-based telehealth intervention was feasible, acceptable, and demonstrated preliminary efficacy in improving fatigue interference, severity, and levels. REVITALIZE is a novel, scalable telehealth intervention worthy of further investigation.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Wright AA, Poort H, Tavormina A, et al. Pilot randomized trial of an acceptance-based telehealth intervention for women with ovarian cancer and PARP inhibitor-related fatigue. Gynecol Oncol. 2023. PMID: 37708581. doi:10.1016/j.ygyno.2023.08.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。